This trial studies how well leflunomide works for the treatment of patients with CD30+
lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment
(refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
I. To evaluate overall response rate of leflunomide treatment.
I. To assess complete response rate and duration of response of leflunomide treatment.
II. To assess toxicities of leflunomide treatment. III. To assess disease status by the CAILS
(composite assessment of index lesion severity).
I. To generate a preliminary ribonucleic acid (RNA) signature associated with response of
CD30+ lymphoproliferative disorders (LYPDs) cells to leflunomide.
Patients receive leflunomide orally (PO) once daily (QD) on days 1-28. Treatment repeats
every 28 days for up to 13 cycles in the absence of disease progression or unacceptable
After completion of study treatment, patients are followed up every 3 months for 12 months.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.